Renal cell carcinoma · 9 regimens
Cost vs Efficacy · 4 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cyclophosphamide and Fludarabine (FC), then allo HSCT Variant #01 | — | R 192 642 | — | — | — | — | — | — |
Cabozantinib monotherapy Variant #01 | — | R 90 983 | 28d | ~9.0 mo | ~16.2 mo | ~10 | ~R 909 829 PFS proxy · indirect | 8 |
Sorafenib monotherapy Variant #04 | — | R 37 339 | 28d | 3.9 mo | — | 5 | R 186 694 PFS proxy | 1 |
Sunitinib monotherapy Variant #05 | — | R 33 433 | 28d | ~9.2 mo | — | ~11 | ~R 367 764 PFS proxy · indirect | 2 |
Everolimus monotherapy Variant #01 | — | R 18 360 | 28d | ~7.9 mo | — | ~9 | ~R 165 237 PFS proxy · indirect | 1 |
Interferon alfa-2a and Isotretinoin Variant #01 | — | R 250 | 7d | — | 17.3 mo | — | — | — |
Interferon alfa-2c monotherapy Variant #01 Partial | — | — | 7d | — | — | — | — | — |
Interferon alfa-2a monotherapy Variant #01 Partial | — | — | 7d | — | ~13.0 mo | — | — | 4 |
Megestrol monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
9 of 9 regimens shown